Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Shares Outstanding (Diluted Average) (2019 - 2025)

Amicus Therapeutics (FOLD) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $308.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 1.31% year-over-year to $308.4 million, compared with a TTM value of $308.4 million through Dec 2025, up 1.31%, and an annual FY2025 reading of $308.4 million, up 1.31% over the prior year.
  • Shares Outstanding (Diluted Average) was $308.4 million for Q4 2025 at Amicus Therapeutics, roughly flat from $308.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $308.4 million in Q4 2025 and bottomed at $265.4 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $295.9 million, with a median of $299.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 6.5% in 2022, then rose 0.99% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $271.4 million in 2021, then rose by 6.5% to $289.1 million in 2022, then increased by 2.11% to $295.2 million in 2023, then increased by 3.12% to $304.4 million in 2024, then increased by 1.31% to $308.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for FOLD at $308.4 million in Q4 2025, $308.1 million in Q3 2025, and $308.3 million in Q2 2025.